Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis

Annals of Pharmacotherapy

Volumn 39, Issue 7-8, 2005, Pages 1182-1187

  Dager, William E ^a,b,c,d   King, Jeff H ^b,d   Branch, Jennifer M ^b,d   Chow, Stacey L ^h   Ferrer, Ruby E ^e   Pak, Sandy ^f   Togioka, Patti Y ^g   White, Richard H ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e LONG BEACH MEMORIAL MEDICAL CENTER   (United States)

^f KAISER PERMANENTE   (United States)

^g VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^h Veterans Affairs Palo Alto Health Care System ^*

Author keywords

Deep vein thrombosis; Low molecular weight heparin; Outpatient treatment; Pulmonary embolism; Tinzaparin

Indexed keywords

ANTIVITAMIN K; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN; WARFARIN;

ADULT; AGED; BLEEDING; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEALTH CARE SYSTEM; HEMATOMA; HEMATURIA; HEMOPTYSIS; HUMAN; INTRAOCULAR HEMORRHAGE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD; OUTPATIENT CARE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SUBDURAL HEMATOMA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; OUTPATIENTS; PLATELET COUNT; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VENOUS THROMBOSIS; WARFARIN;

EID: 21744457102     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E677     Document Type: Review

References (26)

1. van den Belt AGM, Prins MH, Lensing AWA, Castro AA, Clark OAC, Atallah AN, et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2002(2):CD001100. Update: 2004(4):CD001100.
2. White RH. The epidemiology of venous thromboembolism. Circulation 2003;107(23 suppl 1):I4-8.
3. Bullar HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 suppl):401S-428S. Erratum 2005;127:416.
4. Pineo G. New developments in the prevention and treatment of venous thromboembolism. Pharmacotherapy 2001;21(6 pt 2):51S-5S.
5. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheach G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism. Arch Intern Med 2000;160:181-8.
6. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med 2004;140:175-83.
7. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-9.
8. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
9. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337:657-62.
10. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81.
11. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a cost-effectiveness analysis. Ann Intern Med 1999;130:789-99.
12. Lapidus L, Borretzen J, Fahlen M, Thomsen HG, Hasselblom S, Larson L, et al. Home treatment of deep vein thrombosis: an outpatient treatment model with once-daily injection of low-molecular-weight heparin (tinzaparin) in 555 patients. Pathophysiol Haemost Thromb 2002;32:59-66.
13. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-7.
14. Lee M, Pao D, Hsu T, Sonderskov A. Cost savings and effectiveness of outpatient treatment with low molecular weight heparin of deep vein thrombosis in a community hospital. Can J Clin Pharmacol 2004;11:e17-27.
15. Stockelberg D, Hansson E, Jonson T. Treatment of deep vein thrombosis with a low molecular weight heparin at patient's home. J Thromb Thrombolysis 1998;6:169-71.
16. Blattler W, Kreis N, Blattler I. Practicability and quality of outpatient management of deep venous thrombosis. J Vasc Surg 2000;32:855-60.
17. Lindmarker P, Holmstrom M. Use of low molecular weight heparin (dalteparin) once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group. J Intern Med 1996;240:395-401.
18. Savage KJ, Wells PS, Schulz V, Goudie D, Morrow B, Cruickshank M, et al. Outpatient use of low molecular weight heparin (dalteparin) for the treatment of deep vein thrombosis of the upper extremity. Thromb Haemost 1999;82:1008-10.
19. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban J, Azarian R, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997;337:663-9.
20. Hull R, Raskob GE, Brant RF, Pineo GF, Elliott G, Stein PD, et al. Low-molecular weight heparin vs. heparin in the treatment of patients with pulmonary embolism. Arch Intern Med 2000;160:229-36.
21. Hull R, Raskob G, Pineo G, Green D, Trowbridge AA, Elliott CG, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-82.
22. Prescribing information. Innohep (tinzaparin sodium injection). Boulder, CO: Pharmion, January 2003.
23. White RH, Beyth RJ, Zhou H, Romano PS. Major bleeding after hospitalization for deep-venous thrombosis. Am J Med 1999;107:414-24.
24. Deitcher SR, Kessler CM, Lyons RM, Fareed J. Treatment of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period (abstract 1158). Blood 2003;102:322a.
25. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. Ann Intern Med 2004;140:867-73.
26. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al. Subcutaneous fondaparinux versus intravenous unfractionated hep arin in the initial treatment of pulmonary embolism. N Engl J Med 2003;349:1695-702.